Pulse Biosciences, Inc Common Stock (DE) financials
$50.89−2.73%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $350.0K | $0.00 | $0.00 | $700.0K | $1.4M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | -$189.0K | $0.00 | $0.00 | -$11.2M | -$550.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | −54.0% | — | — | −1606.3% | −38.8% | — | — | — | — | — |
| Operating income | -$76.9M | -$56.3M | -$43.6M | -$58.1M | -$63.0M | -$50.0M | -$48.0M | -$38.0M | -$25.8M | -$9.6M |
| Net income | -$72.8M | -$53.6M | -$42.2M | -$58.5M | -$63.7M | -$49.9M | -$47.0M | -$37.5M | -$25.6M | -$9.5M |
| Net margin | −20794.6% | — | — | −8357.9% | −4489.4% | — | — | — | — | — |
| Diluted EPS | $-1.08 | $-0.92 | $-0.85 | $-1.72 | $-2.28 | $-2.14 | $-2.26 | $-2.20 | $-1.73 | $-0.86 |
| EBITDA | -$75.9M | -$55.1M | -$43.0M | -$56.7M | -$61.9M | -$48.9M | -$46.8M | -$36.7M | -$24.8M | -$8.8M |
| Operating cash flow | -$54.1M | -$36.3M | -$32.4M | -$47.9M | -$54.1M | -$35.4M | -$34.2M | -$23.9M | -$11.1M | -$8.1M |
| Free cash flow | -$54.4M | -$36.5M | -$32.5M | -$48.3M | -$54.5M | -$35.8M | -$34.8M | -$24.2M | -$13.6M | -$8.1M |
| Diluted shares | 67.4M | 58.4M | 49.7M | 33.9M | 28.0M | 23.2M | 20.7M | 17.1M | 14.8M | 11.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $80.7M | $118.0M | $44.4M | $61.1M | $44.4M | $12.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $8.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $65.9M | $0.00 | $0.00 |
| Total assets | $94.5M | $132.5M | $59.2M | $77.9M | $59.2M | $41.3M |
| Total liabilities | $13.9M | $17.6M | $14.8M | $80.1M | $14.8M | $18.4M |
| Shareholders' equity | $80.7M | $114.9M | $44.4M | -$2.2M | $44.4M | $22.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology